Case studies demonstrating delivery of complex and innovative trial design
- FOCUS4 - Foundations for fighting COVID-19
Learn how forward-thinking approaches to cancer clinical trials from the last decade have featured in the UK’s fight against COVID-19.
- National Lung Matrix Trial - laying the groundwork for combatting COVID-19
Learn how our history of cutting-edge cancer research underpinned the UK’s COVID-19 research response.
- STAMPEDE - a turning point in trial design
Find out why the STAMPEDE trial is a milestone in the history of clinical trial design in the UK.
- The UK's flagship COVID-19 treatment trial - the RECOVERY trial
The NIHR-supported RECOVERY trial is leading the way in identifying treatments for this new infectious disease.
- REMAP-CAP tests treatments for COVID-19
A nationally-prioritised study which aims to provide answers about the best treatment options for COVID-19 patients who develop pneumonia.
- REMAP-CAP also featured in: Case study: UK achieves site activation world record for Roche during COVID19 pandemic
The UK’s Urgent Public Health response has been applauded by global life science company, Roche
- TAILoR trial: Adopting an adaptive approach to help HIV patients on antiretroviral therapy (cART)
Finding the right dose of any therapy is crucial and adaptive trial designs offer a novel way of finding the most appropriate dose for licensed drugs being repurposed for another indication.
- Using an adaptive model to trial a new treatment for rare kidney disease
An adaptive trial model is being used to investigate a new drug being developed by Novartis, after showing promising results in the lab.
Case studies demonstrating innovative delivery techniques
- CLARITY IBD: Changing the way we do research
CLARITY IBD is recognised in many countries as a triumph in clinical trial delivery. It recruited 7000 participants with inflammatory bowel disease in 12 weeks across 92 sites and rapidly answered key questions on the impact of immunomodulator and biologic therapies on COVID-19 immunity following infection and vaccination - and all that during a pandemic. Learn how digital and decentralised research delivery techniques contributed to this success.
- RELIEVE IBS-D: Pushing virtual boundaries to improve patient engagement and accessibility
Discover how the NIHR and Enteromed collaborated to deliver the UK’s first fully virtual, commercial, interventional trial for Irritable Bowel Syndrome with Diarrhea (IBS-D).
- PD-STAT: Paving the way for the future of remote trial delivery
Learn how the NIHR supported the PD-STAT trial to transition to a virtual model during the COVID-19 pandemic.
- Research register provides rapid access to rare renal disease patients
A research registry in the UK, which provides rapid access to almost 24,000 patients with rare renal disease, is transforming how research in rare renal conditions is done, and making the UK an attractive prospect for new academic and commercial studies.
- NURTuRE: New biobank brings a wealth of new opportunities for UK renal research
Research registries and biobanks present an efficient way of doing research. In the UK the life sciences industry, charities and academia are collaborating to maximise this new approach and open up a wealth of new opportunities to accelerate new advances that will benefit kidney disease patients.
- SIMPLIFIED: Using data to answer to the vitamin D question for dialysis patients
The SIMPLIFIED study is the first renal registry-facilitated trial of its kind.
- Novel social media approach to recruit 40,000 volunteers with experience of depression or anxiety
The GLAD Study utilised social media as a vital tool for getting driving recruitment.
- ROCOCO: Real-world research in a pharmacy setting
The real-world approach adopted by the Rococo study meant that it was the first cough medicine study in the UK to be delivered entirely in a pharmacy setting.
Podcast series looking at complex and innovative trial design and delivery
We have also produced a collection of podcasts designed to inform, educate and answer the common questions around the management and delivery of complex and innovative design (CID) trials. Some of these were created in collaboration with the Health Research Authority (HRA) and are present a range of expert perspectives from both before and during the COVID-19 pandemic.